# Soluble Epoxide Hydrolase Inhibition and Insulin Resistance

> **NCT03486223** · PHASE2 · COMPLETED · sponsor: **Vanderbilt University Medical Center** · enrollment: 16 (actual)

## Conditions studied

- Diabetes Mellitus
- Endocrine System Diseases
- Glucose Metabolism Disorders
- PreDiabetes
- Obesity

## Interventions

- **DRUG:** GSK2256294
- **DRUG:** Placebo oral capsule

## Key facts

- **NCT ID:** NCT03486223
- **Lead sponsor:** Vanderbilt University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-17
- **Primary completion:** 2021-11-18
- **Final completion:** 2021-11-18
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2023-03-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03486223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03486223, "Soluble Epoxide Hydrolase Inhibition and Insulin Resistance". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT03486223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*